Viral diagnostic test kits market seen reaching $24.87B by 2030

The Business Research Company says the viral diagnostic test kits market is growing on higher infection rates, broader PCR adoption and demand for faster detection. The market is projected to rise from $17.48 billion in 2025 to $18.88 billion in 2026, then reach $24.87 billion by 2030.

Why it matters: - Viral diagnostic test kits are becoming more important as outbreaks, early detection needs and decentralized testing all expand. - The market’s forecast growth points to sustained demand for tools that can identify infections faster and support outbreak control.

What happened: - The Business Research Company published a market study on the global viral diagnostic test kits market. - The market is estimated at $17.48 billion in 2025 and is projected to reach $18.88 billion in 2026. - The report forecasts the market will grow to $24.87 billion by 2030. - The company released a free sample of the report at More information. - The full report is available at the full report.

The details: - The 2025 to 2026 growth forecast implies an 8.0% compound annual growth rate. - The 2026 to 2030 forecast implies a 7.1% compound annual growth rate. - Growth drivers include frequent viral outbreaks, expansion of clinical diagnostic laboratories, wider use of PCR-based testing, rising demand for early disease detection and better laboratory infrastructure. - The report expects additional growth from pandemic preparedness, decentralized testing, higher investment in molecular diagnostics, broader home testing access and faster, more sensitive assays. - The report highlights rapid diagnostic kits, molecular viral detection, point-of-care testing, multiplex viral assays and a focus on high-sensitivity accuracy as major trends. - Viral diagnostic test kits detect infections using patient samples such as blood, saliva, nasal swabs and other bodily fluids. - These kits can identify viral particles, antigens, nucleic acids and antibodies through reagents, antibodies or other components that react with viral material. - In April 2025, the Centers for Disease Control and Prevention reported 2,214 new acute hepatitis B cases in 2023, about 14,400 estimated infections after adjusting for underreporting, 17,650 newly reported chronic hepatitis B cases, 4,966 new acute hepatitis C cases and 101,525 new chronic hepatitis C cases. - The report says North America led the market in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period. - The geographic scope includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The growth outlook reflects a market that is moving from outbreak-driven demand to broader routine use in diagnostics and home testing. - The emphasis on sensitivity, speed and decentralization suggests buyers want faster results outside traditional labs, not just more testing capacity.

What's next: - The market’s next phase likely centers on molecular diagnostics, point-of-care platforms and home testing formats. - Regional growth appears most concentrated in Asia-Pacific as healthcare spending and access to diagnostics expand. - The Business Research Company says its 2026 reports add TAM analysis, scoring matrices, forecasting dashboards and updated trend graphics.